{"id":"low-dose-levetiracetam","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Somnolence"},{"rate":"10-25","effect":"Dizziness"},{"rate":"10-15","effect":"Asthenia/fatigue"},{"rate":"5-15","effect":"Behavioral changes/mood changes"},{"rate":"5-10","effect":"Ataxia"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1286","moleculeType":"Small molecule","molecularWeight":"170.21"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levetiracetam is an antiepileptic drug that acts primarily through binding to the synaptic vesicle protein SV2A, which is involved in vesicle exocytosis and neurotransmitter release. At low doses, it provides neuroprotective effects with reduced side effects compared to standard dosing. The exact mechanism of action at the molecular level remains incompletely understood, but SV2A binding is considered the primary mechanism.","oneSentence":"Low-dose levetiracetam reduces neuronal excitability by binding to synaptic vesicle protein SV2A, modulating neurotransmitter release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:16.821Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive therapy)"},{"name":"Myoclonic seizures"},{"name":"Partial-onset seizures"}]},"trialDetails":[{"nctId":"NCT06907173","phase":"PHASE3","title":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2026-02","conditions":"Status Epilepticus","enrollment":770},{"nctId":"NCT05824728","phase":"PHASE2","title":"Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-09-28","conditions":"Parkinson Disease Psychosis","enrollment":30},{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT04836559","phase":"PHASE2","title":"A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-05-18","conditions":"Focal Onset Seizures","enrollment":110},{"nctId":"NCT05986721","phase":"PHASE2","title":"Clinical Trial of AGB101 for Mild Cognitive Impairment","status":"WITHDRAWN","sponsor":"AgeneBio","startDate":"2024-12-03","conditions":"Mild Cognitive Impairment, Prodromal Alzheimer's Disease","enrollment":""},{"nctId":"NCT06919926","phase":"PHASE2","title":"Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-04-17","conditions":"Hippocampal Overactivity, Dementia","enrollment":60},{"nctId":"NCT02647437","phase":"NA","title":"Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-06","conditions":"Schizophrenia","enrollment":18},{"nctId":"NCT05263674","phase":"PHASE3","title":"Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)","status":"RECRUITING","sponsor":"University of Southern Denmark","startDate":"2022-02-07","conditions":"Non-Convulsive Status Epilepticus","enrollment":140},{"nctId":"NCT03875638","phase":"PHASE2","title":"Treating Hyperexcitability in AD With Levetiracetam","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2019-08-22","conditions":"Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type","enrollment":85},{"nctId":"NCT02056236","phase":"NA","title":"TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation","status":"COMPLETED","sponsor":"University of Twente","startDate":"2014-04","conditions":"Cardiac Arrest, Anoxic Encephalopathy, Status Epilepticus","enrollment":172},{"nctId":"NCT01685411","phase":"NA","title":"Busulfan and Cyclophosphamide Followed By ALLO BMT","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-01","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":5},{"nctId":"NCT00615615","phase":"PHASE3","title":"Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"1999-09","conditions":"Epilepsy","enrollment":216},{"nctId":"NCT01554683","phase":"NA","title":"Seizure Activity in Alzheimer's Disease","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2012-02","conditions":"Alzheimer's Disease, Seizures","enrollment":12},{"nctId":"NCT00884052","phase":"PHASE1, PHASE2","title":"Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures","status":"COMPLETED","sponsor":"Richard H. Haas","startDate":"2007-04","conditions":"Seizures, Disorder of Fetus or Newborn","enrollment":18},{"nctId":"NCT01345058","phase":"PHASE3","title":"Add on Lacosamide Versus High Dose Monotherapy","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-08-01","conditions":"Epilepsy","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Keppra","Low levetiracetam"],"phase":"marketed","status":"active","brandName":"Low dose levetiracetam","genericName":"Low dose levetiracetam","companyName":"Richard H. Haas","companyId":"richard-h-haas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose levetiracetam reduces neuronal excitability by binding to synaptic vesicle protein SV2A, modulating neurotransmitter release. Used for Epilepsy (standard indication), Off-label use for anxiety, mood disorders, or neuropathic pain (low-dose formulations).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}